Alan Fuhrman is Director of Esperion Therapeutics, Inc.. Currently has a direct ownership of 53,404 shares of ESPR, which is worth approximately $128,703. The most recent transaction as insider was on May 23, 2024, when has been sold 23,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 53.4K
0% 3M change
75.65% 12M change
Total Value Held $128,703

Alan Fuhrman Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 23 2024
BUY
Grant, award, or other acquisition
-
23,000 Added 30.1%
53,404 Common Stock
Jun 15 2023
BUY
Grant, award, or other acquisition
-
5,150 Added 14.49%
30,404 Common Stock
May 27 2021
BUY
Grant, award, or other acquisition
-
12,376 Added 32.89%
25,254 Common Stock

Also insider at

SWTX
SpringWorks Therapeutics, Inc. Healthcare
CMPI
Checkmate Pharmaceuticals, Inc.
TYRA
Tyra Biosciences, Inc. Healthcare
AF

Alan Fuhrman

Director
Stamford, CT

Track Institutional and Insider Activities on ESPR

Follow Esperion Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR